Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis

Current Opinion in Neurology

Volumn 23, Issue 5, 2010, Pages 530-535

  Guptill, Jeffrey T ^a   Sanders, Donald B ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

muscle specific kinase; muscle specific tyrosine kinase antibody; myasthenia gravis; rituximab; seronegative

Indexed keywords

AZATHIOPRINE; CHOLINESTERASE INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EDROPHONIUM CHLORIDE; IMMUNOGLOBULIN; MUSCLE SPECIFIC TYROSINE KINASE ANTIBODY; MYCOPHENOLIC ACID; PREDNISONE; PROTEIN ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ELECTRODIAGNOSIS; FACE MUSCLE; HEMIFACIAL ATROPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIMB WEAKNESS; MUSCLE ATROPHY; MYASTHENIA GRAVIS; NEUROMUSCULAR TRANSMISSION; PATHOGENESIS; PHENOTYPE; PLASMAPHERESIS; REVIEW; THYMECTOMY; TREATMENT OUTCOME; TREATMENT RESPONSE;

AUTOANTIBODIES; HUMANS; MYASTHENIA GRAVIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC;

EID: 77956395013     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32833c0982     Document Type: Review

References (61)

1. Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7:365-368.
2. Sanders DB, El-Salem K, Massey JM, et al. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003; 60:1978-1980.
3. Romi F, Aarli JA, Gilhus NE. Seronegative myasthenia gravis: disease severity and prognosis. Eur J Neurol 2005; 12:413-418.
4. Zhou L, McConville J, Chaudhry V, et al. Clinical comparison of musclespecific tyrosine kinase (MuSK) antibody-positive and negative myasthenic patients. Muscle Nerve 2004; 30:55-60.
5. Burns T, Wolfe G, Nations S, et al. Variable MuSK antibody positive rates among seronegative MG in the United States. Neurology 2008; 70 (Suppl 1): A302.
6. Yeh JH, Chen WH, Chiu HC, Vincent A. Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese. Neurology 2004; 62:2131-2132.
7. Huang YC, Yeh JH, Chiu HC, Chen WH. Clinical characteristics of MuSK antibody-positive myasthenia gravis in Taiwan. J Formos Med Assoc 2008; 107:572-575.
8. Evoli A, TonaliPA, Padua L, et al. Clinical correlates with anti-MuSKantibodies in generalized seronegative myasthenia gravis. Brain 2003; 126:2304-2311.
9. Scuderi F, Marino M, Colonna L, et al. Anti-P110 autoantibodies identify a subtype of ;seronegative; myasthenia gravis with prominent oculobulbar involvement. Lab Invest 2002; 82:1139-1146.
10. Brealy J, Aziz T, Zangeneh S, Oger J. Muscle specific tyrosine kinase antibody positivity: prevalence and clinical characteristics in western Canada. Neurology 2010; 74 (Suppl 2):A92.
11. Zhang X, Yang M, Xu J, et al. Clinical and serological study of myasthenia gravis in HuBei Province, China. J Neurol Neurosurg Psychiatry 2007; 78:386-390.
12. McConville J, Farrugia ME, Beeson D, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004; 55:580-584.
13. Suhail H, Subbiah V, Singh S, Behari M. MuSK-antibody positive myasthenia gravis and their clinical features in North India. Neurology 2010; 74 (Suppl 2): A91-A92.
14. Nemoto Y, Kuwabara S, Misawa S, et al. Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis. J Neurol Neurosurg Psychiatry 2005; 76:714-718 002E
15. Ohta K, Shigemoto K, Fujinami A, et al. Clinical and experimental features of MuSK antibody positive MG in Japan. Eur J Neurol 2007; 14:1029-1034.
16. Shiraishi H, Motomura M, Yoshimura T, et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 2005; 57:289-293.
17. Lee JY, Sung JJ, Cho JY, et al. MuSK antibody-positive, seronegative myasthenia gravis in Korea. J Clin Neurosci 2006; 13:353-355.
18. Niks EH, Kuks JB, Verschuuren JJ. Epidemiology of myasthenia gravis with antimuscle specific kinase antibodies in The Netherlands. J Neurol Neurosurg Psychiatry 2007; 78:417-418.
19. Illa I, Diaz-Manera JA, Juarez C, et al. ;Seronegative; myasthenia gravis and antiMuSK positive antibodies: description of Spanish series. Med Clin (Barc) 2005; 125:100-102.
20. Chang T, Gunaratne P, Gamage R, et al. MuSK-antibody-positive myasthenia gravis in a South Asian population. J Neurol Sci 2009; 284:33-35.
21. Diaz-Manera J, Rojas-Garcia R, Gallardo E, et al. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan;s syndrome. Nat Clin Pract Neurol 2007; 3:405-410.
22. Sanders DB, Juel VC. MuSK-antibody positive myasthenia gravis: questions from the clinic. J Neuroimmunol 2008; 201:85-89.
23. Rostedt PA, Ahlqvist K, Bartoccioni E, et al. Neurophysiological and mitochondrial abnormalities in MuSK antibody seropositive myasthenia gravis compared to other immunological subtypes. Clin Neurophysiol 2006; 117:1434-1443.
24. Lavrnic D, Losen M, Vujic A, et al. The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry 2005; 76:1099-1102.
25. Stickler DE, Massey JM, Sanders DB. MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns. Clin Neurophysiol 2005; 116:2065-2068.
26. Pasnoor M, Wolfe GI, Nations S, et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve 2010; 41:370-374.
27. Niks EH, Verrips A, Semmekrot BA, et al. A transient neonatal myasthenic syndrome with anti-musk antibodies. Neurology 2008; 70:1215-1216.
28. Behin A, Mayer M, Kassis-Makhoul B, et al. Severe neonatal myasthenia due to maternal anti-MuSK antibodies. Neuromuscul Disord 2008; 18:443-446.
29. Bau V, Hanisch F, Hain B, Zierz S. Ocular involvement in MuSK antibodypositive myasthenia gravis. Klin Monbl Augenheilkd 2006; 223:81-83.
30. Caress JB, Hunt CH, Batish SD. Anti-MuSK myasthenia gravis presenting with purely ocular findings. Arch Neurol 2005; 62:1002-1003.
31. Chan JW, Orrison WW. Ocular myasthenia: a rare presentation with MuSK antibody and bilateral extraocular muscle atrophy. Br J Ophthalmol 2007; 91:842-843.
32. Farrugia ME, Robson MD, Clover L, et al. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 2006; 129:1481-1492.
33. Shigemoto K, Kubo S, Maruyama N, et al. Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest 2006; 116:1016-1024.
34. Kim N, Stiegler AL, Cameron TO, et al. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 2008; 135:334-342.
35. Kong XC, Barzaghi P, Ruegg MA. Inhibition of synapse assembly in mammalian muscle in vivo by RNA interference. EMBO Rep 2004; 5:183-188.
36. Selcen D, Fukuda T, Shen XM, Engel AG. Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology 2004; 62:1945-1950.
37. Bartoccioni E, Scuderi F, Minicuci GM, et al. Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology 2006; 67:505-507.
38. Vincent A. Immunology of disorders of neuromuscular transmission. Acta Neurol Scand 2006; 113:1-7.
39. Bartoccioni E, Scuderi F, Augugliaro A, et al. HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. Neurology 2009; 72:195-197.
40. Niks EH, Kuks JB, Roep BO, et al. Strong association of MuSK antibodypositive myasthenia gravis and HLA-DR14-DQ5. Neurology 2006; 66:1772-1774.
41. Evoli A, Bianchi MR, Riso R, et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann NY Acad Sci 2008; 1132:76-83.
42. Leite MI, Strobel P, Jones M, et al. Fewer thymic changes in MuSK antibodypositive than in MuSK antibody-negative MG. Ann Neurol 2005; 57:444-448.
43. Saka E, Topcuoglu MA, Akkaya B, et al. Thymus changes in anti-MuSKpositive and -negative myasthenia gravis. Neurology 2005; 65:782-783.
44. Hatanaka Y, Hemmi S, Morgan MB, et al. Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG. Neurology 2005; 65:1508-1509.
45. Kuwabara S, Nemoto Y, Misawa S, et al. Anti-MuSK-positive myasthenia gravis: neuromuscular transmission failure in facial and limb muscles. Acta Neurol Scand 2007; 115:126-128.
46. Farrugia ME, Kennett RP, Newsom-Davis J, et al. Single-fiber electromyography in limb and facial muscles in muscle-specific kinase antibody and acetylcholine receptor antibody myasthenia gravis. Muscle Nerve 2006; 33:568-570.
47. Lauriola L, Ranelletti F, Maggiano N, et al. Thymus changes in anti-MuSKpositive and -negative myasthenia gravis. Neurology 2005; 64:536-538.
48. Deymeer F, Gungor-Tuncer O, Yilmaz V, et al. Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis. Neurology 2007; 68:609-611.
49. Jaretzki A III, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000; 55:16-23.
50. Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: rebooting with high-dose cyclophosphamide. Ann Neurol 2003; 53:29-34.
51. Lin PT, Martin BA, Weinacker AB, So YT. High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies. Muscle Nerve 2006; 33:433-435.
52. Baek WS, Bashey A, Sheean GL. Complete remission induced by rituximab in refractory, seronegative, muscle-specific kinase-positive myasthenia gravis. J Neurol Neurosurg Psychiatry 2007; 78:771.
53. Gardner R, Pestronk A, Al-Lozi M. Intractable myasthenia gravis responding to rituximab treatment. Neurology 2008; 70 (Suppl 1):A301.
54. Hain B, Jordan K, Deschauer M, Zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 2006; 33:575-580.
55. Illa I, Diaz-Manera J, Rojas-Garcia R, et al. Sustained response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients. J Neuroimmunol 2008; 201:90-94.
56. Lebrun C, Bourg V, Tieulie N, Thomas P. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol 2009; 16:246-250.
57. Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2010 [Epub ahead of print].
58. Stieglbauer K, Topakian R, Schaffer V, Aichner FT. Rituximab for myasthenia gravis: three case reports and review of the literature. J Neurol Sci 2009; 280:120-122.
59. Thakre M, Inshasi J, Marashi M. Rituximab in refractory MuSK antibody myasthenia gravis. J Neurol 2007; 254:968-969.
60. Zebardast N, Patwa HS, Novella SP, Goldstein JM. Rituximab in the management of refractory myasthenia gravis. Muscle Nerve 2010; 41:375-378.
61. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010; 9:425-437.